Bank Of America Corp Kezar Life Sciences, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 105,389 shares of KZR stock, worth $61,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,389

Previous 33,249 216.97%

Holding current value

$61,125

Previous $29,000 117.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.6 - $0.92 $43,284 - $66,368	72,140 Added 216.97%	105,389 $63,000
Q1 2024 May 15, 2024	SELL	$0.8 - $1.05 $44,793 - $58,791	-55,992 Reduced 62.74%	33,249 $29,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $27,676 - $44,204	38,439 Added 75.66%	89,241 $84,000
Q2 2023 Aug 14, 2023	SELL	$2.31 - $3.06 $616,649 - $816,860	-266,948 Reduced 84.01%	50,802 $124,000
Q1 2023 May 12, 2023	SELL	$3.13 - $7.31 $86,312 - $201,580	-27,576 Reduced 7.99%	317,750 $994,000
Q4 2022 Feb 10, 2023	BUY	$6.39 - $8.8 $725,245 - $998,773	113,497 Added 48.96%	345,326 $2.43 Million
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $1.75 Million - $2.36 Million	219,354 Added 1758.35%	231,829 $2 Million
Q2 2022 Aug 12, 2022	SELL	$4.58 - $17.13 $176,229 - $659,128	-38,478 Reduced 75.52%	12,475 $103,000
Q1 2022 May 16, 2022	SELL	$12.3 - $18.33 $1.2 Million - $1.78 Million	-97,207 Reduced 65.61%	50,953 $847,000
Q4 2021 Feb 08, 2022	BUY	$7.44 - $16.72 $684,785 - $1.54 Million	92,041 Added 164.01%	148,160 $2.48 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $9.73 $163,217 - $327,443	33,653 Added 149.8%	56,119 $484,000
Q2 2021 Sep 13, 2021	BUY	$4.93 - $6.46 $110,757 - $145,130	22,466 New	22,466 $122,000

Others Institutions Holding KZR

# of Institutions

Shares Held

39.6M

Call Options Held

3.2K

Put Options Held

700

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $39.7M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Kezar Life Sciences, Inc. Transaction History